NTLA icon

Intellia Therapeutics

9.62 USD
+0.32
3.44%
At close Mar 12, 4:00 PM EDT
After hours
9.60
-0.02
0.21%
1 day
3.44%
5 days
6.89%
1 month
1.16%
3 months
-29.06%
6 months
-53.46%
Year to date
-21.28%
1 year
-65.37%
5 years
-12.55%
10 years
-56.47%
 

About: Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Employees: 598

0
Funds holding %
of 7,372 funds
0
Analysts bullish %
of 11 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

91% more repeat investments, than reductions

Existing positions increased: 126 | Existing positions reduced: 66

43% more call options, than puts

Call options by funds: $16.5M | Put options by funds: $11.5M

33% more first-time investments, than exits

New positions opened: 65 | Existing positions closed: 49

5.09% more ownership

Funds ownership: 92.39% [Q3] → 97.47% (+5.09%) [Q4]

4% more funds holding

Funds holding: 280 [Q3] → 291 (+11) [Q4]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]

39% less capital invested

Capital invested by funds: $1.93B [Q3] → $1.17B (-$758M) [Q4]

Research analyst outlook

11 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$11
14%
upside
Avg. target
$33
244%
upside
High target
$68
607%
upside

11 analyst ratings

positive
64%
neutral
36%
negative
0%
HC Wainwright & Co.
Mitchell Kapoor
30% 1-year accuracy
54 / 181 met price target
212%upside
$30
Buy
Initiated
5 Mar 2025
Truist Securities
Joon Lee
56% 1-year accuracy
24 / 43 met price target
420%upside
$50
Buy
Maintained
4 Mar 2025
Barclays
Gena Wang
17% 1-year accuracy
5 / 30 met price target
170%upside
$26
Overweight
Maintained
28 Feb 2025
Citigroup
David Lebowitz
37% 1-year accuracy
7 / 19 met price target
46%upside
$14
Neutral
Maintained
28 Feb 2025
Wells Fargo
Yanan Zhu
7% 1-year accuracy
1 / 14 met price target
420%upside
$50
Overweight
Maintained
28 Feb 2025

Financial journalist opinion

Based on 278 articles about NTLA published over the past 30 days

Neutral
PRNewsWire
41 minutes ago
Lost Money on Intellia Therapeutics, Inc.(NTLA)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
NEW YORK , March 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA). Shareholders who purchased shares of NTLA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Lost Money on Intellia Therapeutics, Inc.(NTLA)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
Neutral
Accesswire
13 hours ago
Shareholders of Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights – NTLA
NEW YORK, NY / ACCESS Newswire / March 12, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=135608&wire=1 or contact Joseph E. Levi, Esq.
Shareholders of Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights – NTLA
Neutral
Accesswire
14 hours ago
Shareholders of Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA
NEW YORK, NY / ACCESS Newswire / March 12, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=135595&wire=1 or contact Joseph E. Levi, Esq.
Shareholders of Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA
Neutral
GlobeNewsWire
14 hours ago
NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Intellia Therapeutics, Inc. (“Intellia” or “the Company”) (NASDAQ: NTLA) and certain of its officers.
NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Neutral
Accesswire
23 hours ago
Shareholders that lost money on Intellia Therapeutics, Inc.(NTLA) should contact Levi & Korsinsky about pending Class Action - NTLA
NEW YORK, NY / ACCESS Newswire / March 12, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=135430&wire=1 or contact Joseph E. Levi, Esq.
Shareholders that lost money on Intellia Therapeutics, Inc.(NTLA) should contact Levi & Korsinsky about pending Class Action - NTLA
Neutral
Accesswire
23 hours ago
NTLA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Intellia Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESS Newswire / March 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Intellia Therapeutics, Inc. ("Intellia" or "the Company") (NASDAQ:NTLA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Intellia securities between July 30, 2024 and January 8, 2025, both dates inclusive (the "Class Period").
NTLA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Intellia Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
Neutral
PRNewsWire
1 day ago
Shareholders that lost money on Intellia Therapeutics, Inc.(NTLA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
NEW YORK , March 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Intellia investors who were adversely affected by alleged securities fraud between July 30, 2024 and January 8, 2025.
Shareholders that lost money on Intellia Therapeutics, Inc.(NTLA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Neutral
Accesswire
1 day ago
Intellia Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights – NTLA
NEW YORK, NY / ACCESS Newswire / March 11, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=135389&wire=1 or contact Joseph E. Levi, Esq.
Intellia Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights – NTLA
Neutral
Accesswire
1 day ago
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
NEW YORK, NY / ACCESS Newswire / March 11, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ:NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the "Class Period"), of the important April 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Intellia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Neutral
Accesswire
1 day ago
Investors in Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights – NTLA
NEW YORK, NY / ACCESS Newswire / March 11, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=135356&wire=1 or contact Joseph E. Levi, Esq.
Investors in Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights – NTLA
Charts implemented using Lightweight Charts™